Reticular
Interpretable AI for drug discovery
San Francisco, United States · Founded 2024 · $500K raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2024
- Website
- reticular.ai
- Total Funding
- $500K
- Last Round
- $500K Pre-SeedNov 2024
- Rounds
- 1
About
Reticular helps pharma companies discover drugs with AI models like AlphaFold by making them steerable, just like you can prompt LLMs. Today, limited validation data means companies spend millions on failed experiments trying to steer these models through trial and error. We’re piloting our AI interpretability technology with early-stage biotechs and scaling rapidly. Just a week after our pivot, we identified the first interpretable features ever found in protein models, allowing precise control over biological functions. Nithin and John met competing in Biology Olympiads before spending 4 years as roommates at MIT publishing ML/bio research in NeurIPS and Nature. We believe biological models encode far more information than anyone is currently using - our goal is to unlock this potential.
Summary
Reticular is a Biotech company based in San Francisco, United States, founded in 2024. It has raised $500K in total across 1 round, most recently a $500K Pre-Seed round in Nov 2024. Investors include Y Combinator Continuity Fund, BoxGroup and CRV (Charles River).
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2024
Investors
Similar Companies

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...


